Abbott announced on May 26 that it will present 11 abstracts with new evidence across the cancer care continuum at the American Society of Clinical Oncology Annual Meeting, scheduled for May 29 to June 2, 2026, in Chicago. The presentations will highlight Abbott’s integrated cancer diagnostics portfolio and demonstrate how its tests support key decision points from identifying risk and early detection to guiding treatment and monitoring recurrence.
The company said the data indicate a shift in oncology toward more precise detection, improved personalized care, and clearer treatment decisions without adding patient burden or stress. Jake Orville, senior vice president of Abbott’s cancer diagnostics business, said, “Cancer care is at an inflection point, and diagnostics are playing an increasingly central role in how the disease is detected, treated and managed. By combining tools used for screening, early detection, treatment guidance and recurrence monitoring, we’re helping clinicians make more informed decisions at every stage of cancer care, from risk through remission.”
Among the featured studies are results from Abbott’s Cancerguard Multi-Cancer Early Detection Test presented in sessions on June 1. These include research on five-year screening behaviors among DETECT-A participants; a clinical validation study of a multi-biomarker class MCED test in Japan; and a prospective evaluation of psychological impact using smartphone-based patient-reported outcomes.
Additional presentations cover Abbott’s Oncodetect Molecular Residual Disease Test with findings from whole-exome and whole-genome sequencing MRD assays in patients with early triple-negative breast cancer participating in the PARTNER trial. Other studies examine characteristics of patients undergoing molecular residual disease testing with tumor-informed assays.
The Oncotype DX Breast Recurrence Score Test will also be highlighted through AI-driven risk stratification research for distant recurrence in node-positive ER+/HER2- early breast cancer as well as studies evaluating neoadjuvant versus adjuvant chemotherapy strategies for high-risk HR+/HER2- breast cancers. Pipeline innovations include development work on an endometrial cancer test using vaginal swabs.
According to Abbott’s description of its operations included with the announcement, the company employs approximately 122,000 people worldwide serving individuals across more than 160 countries.
